

# Financial Tear Sheet

## Corporate Profile

Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute. In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology achieved objective and complete response criteria, respectively.

Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

In addition to metastatic malignant melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

## Primary IR Contact

### **Stern Investor Relations, Inc.**

Sarah McCabe

Phone: 212-362-1200

E-mail:

[sarah@sternir.com](mailto:sarah@sternir.com)

## Stock Performance

### IOVA (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$14.85**

Change (%) **▲ 0.50 (3.48%)**

Volume 842,131

52 Week High \$19.90

52 Week Low \$4.45

Market Cap \$1,283,546,556

Rolling EPS -1.41

PE Ratio 0

Shares Outstanding 89,445,753

Data as of April 25, 2018 4:00 p.m. ET



## Recent Headlines

March 12, 2018

[Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update](#)

March 8, 2018

[Iovance Biotherapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial Results and Provide a Corporate Update on Monday, March 12, 2018](#)

March 7, 2018

[Iovance Biotherapeutics to Present at Two Upcoming Investor Conferences in March](#)

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
April 25, 2018	<a href="#">DEF 14A</a>
April 6, 2018	<a href="#">8-K</a>
March 19, 2018	<a href="#">4</a>
March 19, 2018	<a href="#">3</a>

## Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.

---

© 2017 Lion Biotechnologies, Inc. All Rights Reserved.